रिस्पेरिडोन के इंटरैक्शन

हम जिन FDA लेबल और फैक्ट शीट को इंडेक्स करते हैं, उनमें रिस्पेरिडोन (Risperdal, Perseris; एंटीसाइकोटिक) के 385 इंटरैक्शन दर्ज हैं: 115 गंभीर, 249 मध्यम, 15 मामूली, और 6 ऐसे जिनमें लेबल बताता है कि कोई महत्वपूर्ण इंटरैक्शन नहीं है। नीचे की हर प्रविष्टि उस वाक्य को उद्धृत करती है जिस पर वह आधारित है। दवा का यह पेज एक शुरुआती बिंदु है, आपकी स्थिति के लिए कोई फ़ैसला नहीं।

लेबल से लिए गए इंटरैक्शन

गंभीर इंटरैक्शन (115)

  • अल्प्राज़ोलमबेंज़ोडायज़ेपिनगंभीर

    • Effects on Driving and Operating Machinery: Patients receiving • alprazolam XR should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. (अल्प्राज़ोलम लेबल, चेतावनियां और सावधानियां)

  • Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (आइवाब्राडिन लेबल, चेतावनियां और सावधानियां)

  • इलोपेरिडोनएंटीसाइकोटिकगंभीर

    Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis In placebo-controlled trials in elderly subjects with dementia, patients randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. (इलोपेरिडोन लेबल, चेतावनियां और सावधानियां)

  • एज़िथ्रोमाइसिनमैक्रोलाइड एंटीबायोटिकगंभीर

    This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (एज़िथ्रोमाइसिन लेबल, चेतावनियां और सावधानियां)

  • एज़ेलास्टिन और फ्लुटिकासोनएंटीहिस्टामिनगंभीर

    • Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (एज़ेलास्टिन और फ्लुटिकासोन लेबल, चेतावनियां और सावधानियां)

  • एटाज़ानाविरएंटीरेट्रोवायरलगंभीर

    …phenobarbital, phenytoin Antiarrhythmics Amiodarone (with ritonavir), quinidine (with ritonavir) Antimycobacterials Rifampin Antineoplastics Apalutamide, encorafenib, irinotecan, ivosidenib Antipsychotics Lurasidone (with ritonavir), pimozide Benzodiazepines Orally administered midazolam a , triazolam Ergot Derivatives Dihydroergotamine, ergonovine, ergotamine, methylergonovine… (एटाज़ानाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (एमट्रिसिटाबिन, रिल्पिविरिन और टेनोफोविर लेबल, चेतावनियां और सावधानियां)

  • एमियोडेरोनएंटीएरिदमिकगंभीर

    Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. (एमियोडेरोन लेबल, चेतावनियां और सावधानियां)

  • एमोक्सापिनट्राइसाइक्लिक एंटीडिप्रेसेंटगंभीर

    …the description of tardive dyskinesia and its clinical detection, please refer to the sections on Information for Patients and ADVERSE REACTIONS . ) Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs and with amoxapine. (एमोक्सापिन लेबल, चेतावनियां)

  • Alpha 1-adrenoreceptor antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine Herbal Products: St. (एल्विटेग्राविर, कोबिसिस्टैट, एमट्रिसिटाबिन और टेनोफोविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एसेनापिनएंटीसाइकोटिकगंभीर

    Cerebrovascular Adverse Events, Including Stroke, In Elderly Patients with Dementia-Related Psychosis In placebo-controlled trials in elderly subjects with dementia, patients randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. (एसेनापिन लेबल, चेतावनियां और सावधानियां)

  • एस्ज़ोपिक्लोनसेडेटिव-हिप्नोटिक (नींद की दवा)गंभीर

    The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (एस्ज़ोपिक्लोन लेबल, चेतावनियां और सावधानियां)

  • एस्टाज़ोलमबेंज़ोडायज़ेपिनगंभीर

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (एस्टाज़ोलम लेबल, चेतावनियां)

  • ऑक्साज़ेपामबेंज़ोडायज़ेपिनगंभीर

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (ऑक्साज़ेपाम लेबल, चेतावनियां)

  • Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (ऑक्सालिप्लैटिन लेबल, दवाओं के इंटरैक्शन)

  • ऑक्सीकोडोनओपिओइडगंभीर

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीकोडोन लेबल, बॉक्स्ड चेतावनी)

  • …LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Oxycodone hydrochloride tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (ऑक्सीकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

  • ऑक्सीमॉर्फोनओपिओइडगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ओलिसेरिडिनओपिओइडगंभीर

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ओलिसेरिडिन लेबल, बॉक्स्ड चेतावनी)

  • ओलोपाटाडीनएंटीहिस्टामिनगंभीर

    • Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (ओलोपाटाडीन लेबल, चेतावनियां और सावधानियां)

  • ओलोपाटाडीन और मोमेटासोनएंटीहिस्टामिनगंभीर

    • Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (ओलोपाटाडीन और मोमेटासोन लेबल, चेतावनियां और सावधानियां)

  • कार्बामाज़ेपिनएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (कार्बामाज़ेपिन लेबल, दवाओं के इंटरैक्शन)

  • कार्बिनोक्सामिनएंटीहिस्टामिनगंभीर

    Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (कार्बिनोक्सामिन लेबल, चेतावनियां और सावधानियां)

  • कीटोकोनाज़ोलएज़ोल एंटीफंगलगंभीर

    This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. (कीटोकोनाज़ोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • केटामिनCNS डिप्रेसेंटगंभीर

    Benzodiazepines, Opioid Analgesics, or other CNS Depressants : Concomitant use may result in profound sedation, respiratory depression, coma, or death. (केटामिन लेबल, दवाओं के इंटरैक्शन)

  • कैरिप्राज़िनएंटीसाइकोटिकगंभीर

    Cerebrovascular Adverse Reactions, Including Stroke , in Elderly Patients with Dementia -Related Psychosis In placebo-controlled trials in elderly patients with dementia, patients randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. (कैरिप्राज़िन लेबल, चेतावनियां और सावधानियां)

  • कोडीनओपिओइडगंभीर

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (कोडीन लेबल, बॉक्स्ड चेतावनी)

  • क्लैरिथ्रोमाइसिनमैक्रोलाइड एंटीबायोटिकगंभीर

    Colchicine (in patients with normal renal and hepatic function) Use With Caution Antipsychotics: Pimozide Contraindicated Pimozide: [See Contraindications ( 4.2 )] Quetiapine Lurasidone Quetiapine: Quetiapine is a substrate for CYP3A4, which is inhibited by clarithromycin. (क्लैरिथ्रोमाइसिन लेबल, दवाओं के इंटरैक्शन)

  • क्लोनाज़ेपामबेंज़ोडायज़ेपिनगंभीर

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोनाज़ेपाम लेबल, चेतावनियां)

  • क्लोनिडिनअल्फा-एड्रीनर्जिक एगोनिस्टगंभीर

    Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (क्लोनिडिन लेबल, चेतावनियां और सावधानियां)

  • क्लोबाज़ामबेंज़ोडायज़ेपिनगंभीर

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोबाज़ाम लेबल, चेतावनियां और सावधानियां)

  • क्लोरडायज़ेपॉक्साइडबेंज़ोडायज़ेपिनगंभीर

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोरडायज़ेपॉक्साइड लेबल, चेतावनियां)

  • Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोरडायज़ेपॉक्साइड और क्लिडिनियम लेबल, चेतावनियां)

  • क्लोराज़ेपेटबेंज़ोडायज़ेपिनगंभीर

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोराज़ेपेट लेबल, चेतावनियां)

  • क्वेटियापिनएंटीसाइकोटिकगंभीर

    Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), including fatalities,… (क्वेटियापिन लेबल, चेतावनियां और सावधानियां)

  • गैबापेंटिनएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    • Respiratory Depression: May occur with NEURONTIN when used with concomitant central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment. (गैबापेंटिन लेबल, चेतावनियां और सावधानियां)

  • ज़िप्रासिडोनएंटीसाइकोटिकगंभीर

    …Warnings and Precautions ( 5.2 ) ] 5.2 Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis In placebo-controlled trials in elderly subjects with dementia, patients randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. (ज़िप्रासिडोन लेबल, चेतावनियां और सावधानियां)

  • ज़ेलेप्लॉनसेडेटिव-हिप्नोटिक (नींद की दवा)गंभीर

    The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (ज़ेलेप्लॉन लेबल, चेतावनियां)

  • ज़ोल्पिडेमसेडेटिव-हिप्नोटिक (नींद की दवा)गंभीर

    The use of Zolpidem Tartrate with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended. (ज़ोल्पिडेम लेबल, चेतावनियां और सावधानियां)

  • टेट्राबेनाज़िनVMAT2 इनहिबिटरगंभीर

    Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with tetrabenazine tablets and other drugs that reduce dopaminergic transmission [see Drug Interactions (7.6) ]. (टेट्राबेनाज़िन लेबल, चेतावनियां और सावधानियां)

  • टेपेंटाडोलओपिओइडगंभीर

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (टेपेंटाडोल लेबल, बॉक्स्ड चेतावनी)

  • टेमाज़ेपामबेंज़ोडायज़ेपिनगंभीर

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (टेमाज़ेपाम लेबल, चेतावनियां)

  • Avoid trimethobenzamide hydrochloride capsules in patients receiving other drugs that are likely to cause EPS (e.g. antipsychotics) [see Drug Interactions (7.2) ] . (ट्राइमेथोबेंज़ामाइड लेबल, चेतावनियां और सावधानियां)

  • ट्राइहेक्सीफेनिडिलएंटीकोलिनर्जिकगंभीर

    Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

  • ट्रामाडोलओपिओइडगंभीर

    Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ट्रामाडोल लेबल, बॉक्स्ड चेतावनी)

  • Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ट्रामाडोल और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

  • ट्रायज़ोलमबेंज़ोडायज़ेपिनगंभीर

    • Effects on Driving and Operating Heavy Machinery : Patients receiving triazolam should be cautioned against driving or operating heavy machinery, as well as avoiding concomitant use with alcohol and other CNS depressant drugs. (ट्रायज़ोलम लेबल, चेतावनियां और सावधानियां)

  • CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (डाइफेनोक्सिलेट और एट्रोपिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • डायज़ेपामबेंज़ोडायज़ेपिनगंभीर

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (डायज़ेपाम लेबल, चेतावनियां)

  • डारुनाविरएंटीरेट्रोवायरलगंभीर

    Alpha 1-adrenoreceptor antagonist: alfuzosin Anti-gout: colchicine, in patients with renal and/or hepatic impairment Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Cardiac Disorders: dronedarone, ivabradine, ranolazine Ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine Herbal product: St. (डारुनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • डारुनाविर और कोबिसिस्टैटएंटीरेट्रोवायरलगंभीर

    …antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Anti-gout: colchicine, in patients with renal and/or hepatic impairment Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Cardiac Disorders: dronedarone, ivabradine, ranolazine Ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine Herbal product: St. (डारुनाविर और कोबिसिस्टैट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • डॉक्सीलामिन और पाइरिडोक्सिनएंटीहिस्टामिनगंभीर

    Central nervous system (CNS) depressants: Concurrent use with alcohol or other CNS depressants is not recommended ( 5.1 ) (डॉक्सीलामिन और पाइरिडोक्सिन लेबल, चेतावनियां और सावधानियां)

  • डोफेटिलाइडएंटीएरिदमिकगंभीर

    Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. (डोफेटिलाइड लेबल, चेतावनियां)

  • ड्यूटेट्राबेनाज़िनVMAT2 इनहिबिटरगंभीर

    Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (ड्यूटेट्राबेनाज़िन लेबल, चेतावनियां और सावधानियां)

  • ड्रोनेडेरोनएंटीएरिदमिकगंभीर

    …Clinical Pharmacology (12.3) ] • Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of torsade de pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics • Liver or lung toxicity related to the previous use of amiodarone… (ड्रोनेडेरोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • थायोरिडाज़िनएंटीसाइकोटिकगंभीर

    …proarrhythmic effects, thioridazine should be reserved for use in the treatment of schizophrenic patients who fail to show an acceptable response to adequate courses of treatment with other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs (see WARNINGS , CONTRAINDICATIONS… (थायोरिडाज़िन लेबल, बॉक्स्ड चेतावनी)

  • नालबुफिनओपिओइडगंभीर

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (नालबुफिन लेबल, बॉक्स्ड चेतावनी)

  • नाल्मेफीनओपिओइड एंटागोनिस्टगंभीर

    Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (नाल्मेफीन लेबल, चेतावनियां और सावधानियां)

  • …Antiarrhythmic: amiodarone, dronedarone, flecainide, propafenone, quinidine • Anti-gout: colchicine (in patients with renal and/or hepatic impairment [see Table 2 , Drug Interactions (7.3)] ) • Antipsychotics: lurasidone, pimozide • Benign prostatic hyperplasia agents: silodosin • Cardiovascular agents: eplerenone, ivabradine • Ergot derivatives: dihydroergotamine, ergotamine,… (निर्माट्रेल्विर और रिटोनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (पाज़ोपैनिब लेबल, दवाओं के इंटरैक्शन)

  • पिटोलिसेंटQT अंतराल बढ़ाने वाली दवागंभीर

    The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

  • पिमोज़ाइडएंटीसाइकोटिकगंभीर

    Because pimozide prolongs the QT interval of the electrocardiogram it is contraindicated in patients with congenital long QT syndrome, patients with a history of cardiac arrhythmias, patients taking other drugs which prolong the QT interval of the electrocardiogram or patients with known hypokalemia or hypomagnesemia (see also PRECAUTIONS - DRUG INTERACTIONS ). (पिमोज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • …MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Pentazocine and Naloxone Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (पेंटाज़ोसिन और नालोक्सोन लेबल, बॉक्स्ड चेतावनी)

  • पेथिडीनओपिओइडगंभीर

    Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (पेथिडीन लेबल, बॉक्स्ड चेतावनी)

  • Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (पैरासिटामोल और कोडीन लेबल, बॉक्स्ड चेतावनी)

  • पैलिपेरिडोनएंटीसाइकोटिकगंभीर

    RISPERDAL CONSTA is contraindicated in patients with a known hypersensitivity to either risperidone or paliperidone, or to any of the excipients in the RISPERDAL CONSTA formulation. (रिस्पेरिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • प्रीगैबलिनएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    • Respiratory Depression : May occur with LYRICA when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. (प्रीगैबलिन लेबल, चेतावनियां और सावधानियां)

  • प्रोपाफेनोनएंटीएरिदमिकगंभीर

    • Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (प्रोपाफेनोन लेबल, चेतावनियां और सावधानियां)

  • …PROMETHAZINE AND RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Promethazine HCl and Codeine Phosphate Oral Solution exposes patients and other users to the risks… (प्रोमेथाज़िन और कोडीन लेबल, बॉक्स्ड चेतावनी)

  • फेंटानिलओपिओइडगंभीर

    • Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (फेंटानिल लेबल, बॉक्स्ड चेतावनी)

  • फेनेलज़िनMAO इनहिबिटरगंभीर

    Phenelzine sulfate should not be used in combination with dextromethorphan or with CNS depressants such as alcohol and certain narcotics. (फेनेलज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • फेनोबार्बिटोनबार्बिट्यूरेटगंभीर

    CNS depressants: Closely monitor for sedation and respiratory depression. (फेनोबार्बिटोन लेबल, दवाओं के इंटरैक्शन)

  • फॉस्कारनेटएंटीवायरलगंभीर

    (See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (फॉस्कारनेट लेबल, दवाओं के इंटरैक्शन)

  • फॉस्फोमाइसिनएंटीबायोटिकगंभीर

    Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (फॉस्फोमाइसिन लेबल, दवाओं के इंटरैक्शन)

  • फोसएम्प्रेनाविरएंटीरेट्रोवायरलगंभीर

    …coadministered with the following drugs: Alpha 1-adrenoreceptor antagonist: Alfuzosin Antiarrhythmics: Flecainide (with ritonavir ), propafenone (with ritonavir ) Antimycobacterial: Rifampin Antipsychotic: Lurasidone (with ritonavir ), pimozide Ergot derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine GI motility agent: Cisapride Herbal product: St. (फोसएम्प्रेनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • फ्लुकोनाज़ोलएज़ोल एंटीफंगलगंभीर

    Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (फ्लुकोनाज़ोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • बेलाडोना और ओपियमओपिओइडगंभीर

    …AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH ALCOHOL, BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Belladonna and opium suppositories expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (बेलाडोना और ओपियम लेबल, बॉक्स्ड चेतावनी)

  • Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूटाल्बिटल, एस्पिरिन, कैफीन और कोडीन लेबल, बॉक्स्ड चेतावनी)

  • Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूटाल्बिटल, पैरासिटामोल, कैफीन और कोडीन लेबल, बॉक्स्ड चेतावनी)

  • ब्यूटॉर्फेनॉलओपिओइडगंभीर

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूटॉर्फेनॉल लेबल, बॉक्स्ड चेतावनी)

  • ब्यूप्रेनॉर्फिनओपिओइडगंभीर

    Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूप्रेनॉर्फिन लेबल, बॉक्स्ड चेतावनी)

  • ब्रेक्सपिप्राज़ोलएंटीसाइकोटिकगंभीर

    Cerebrovascular Adverse Reactions Including Stroke in Elderly Patients with Dementia-Related Psychosis In placebo-controlled trials in elderly patients with dementia, patients randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

  • ब्रोमोक्रिप्टिनडोपामिन एगोनिस्टगंभीर

    The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (ब्रोमोक्रिप्टिन लेबल, चेतावनियां और सावधानियां)

  • मिडाज़ोलमबेंज़ोडायज़ेपिनगंभीर

    WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS Personnel and Equipment for Monitoring and Resuscitation Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer… (मिडाज़ोलम लेबल, बॉक्स्ड चेतावनी)

  • मिर्टाज़ापिनएंटीडिप्रेसेंटगंभीर

    Examples diazepam, alprazolam, alcohol Drugs that Prolong QTc Interval Clinical Impact The concomitant use of other drugs which prolong the QTc interval with REMERON/REMERONSolTab, increase the risk of QT prolongation and/or ventricular arrhythmias (e.g., Torsades de Pointes). (मिर्टाज़ापिन लेबल, दवाओं के इंटरैक्शन)

  • मेटाक्सालोनमसल रिलैक्सेंटगंभीर

    If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. (मेटाक्सालोन लेबल, चेतावनियां और सावधानियां)

  • मेटोक्लोप्रामाइडडोपामिन एंटागोनिस्टगंभीर

    • Tardive Dyskinesia (TD), Other Extrapyramidal Symptoms (EPS), and Neuroleptic Malignant Syndrome (NMS) : Avoid concomitant use of other drugs known to cause TD/EPS/NMS and avoid use in patients with Parkinson’s Disease. (मेटोक्लोप्रामाइड लेबल, चेतावनियां और सावधानियां)

  • मेथाडोनओपिओइडगंभीर

    Managing Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, is a risk factor for respiratory depression and death [see Warnings and Precautions ( 5.2 )]. (मेथाडोन लेबल, बॉक्स्ड चेतावनी)

  • मॉर्फिनओपिओइडगंभीर

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (मॉर्फिन लेबल, बॉक्स्ड चेतावनी)

  • रिटोनाविरएंटीरेट्रोवायरलगंभीर

    WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (रिटोनाविर लेबल, बॉक्स्ड चेतावनी)

  • रिफैम्पिसिनएंटीबायोटिकगंभीर

    …Concomitant use of clopidogrel and rifampin should be discouraged Increase active metabolite exposure and risk of bleeding Ticagrelor Prevention or Management: Avoid use Decrease exposure Antipsychotics Haloperidol Decrease plasma concentrations by 70% Lurasidone Prevention or Management: Concomitant use is contraindicated (See CONTRAINDICATIONS ) Decrease exposure Oral… (रिफैम्पिसिन लेबल, दवाओं के इंटरैक्शन)

  • रेमिफेंटानिलओपिओइडगंभीर

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (रेमिफेंटानिल लेबल, बॉक्स्ड चेतावनी)

  • लुमाटेपेरोनएंटीसाइकोटिकगंभीर

    Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (लुमाटेपेरोन लेबल, चेतावनियां और सावधानियां)

  • लेवॉर्फेनॉलओपिओइडगंभीर

    Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (लेवॉर्फेनॉल लेबल, बॉक्स्ड चेतावनी)

  • लेवोफ्लॉक्सासिनफ्लुओरोक्विनोलोनगंभीर

    Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) (लेवोफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

  • लेवोसेटिरिज़िनएंटीहिस्टामिनगंभीर

    Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (लेवोसेटिरिज़िन लेबल, चेतावनियां और सावधानियां)

  • लोपिनाविर और रिटोनाविरएंटीरेट्रोवायरलगंभीर

    Alpha 1- Adrenoreceptor Antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anti-gout: colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine GI Motility Agent: cisapride Hepatitis C direct acting antiviral: elbasvir/grazoprevir HMG-CoA Reductase Inhibitors: lovastatin, simvastatin… (लोपिनाविर और रिटोनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • लोराज़ेपामबेंज़ोडायज़ेपिनगंभीर

    Caution patients receiving LOREEV XR against operating machinery or driving a motor vehicle as well to avoid the concomitant use of alcohol and other CNS depressant drugs during treatment ( 5.4 , 7 ) (लोराज़ेपाम लेबल, चेतावनियां और सावधानियां)

  • ल्यूरासिडोनएंटीसाइकोटिकगंभीर

    Cerebrovascular Adverse Reactions, Including Stroke in Elderly Patients with Dementia-Related Psychosis In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), including fatalities,… (ल्यूरासिडोन लेबल, चेतावनियां और सावधानियां)

  • वाल्बेनाज़िनVMAT2 इनहिबिटरगंभीर

    Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (वाल्बेनाज़िन लेबल, चेतावनियां और सावधानियां)

  • Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (वेपडेजेस्ट्रेंट लेबल, चेतावनियां और सावधानियां)

  • शराब (अल्कोहल)शराब (अल्कोहल)गंभीर

    Avoid alcohol. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • Avoid the concomitant use of drugs known to prolong the QTc interval. (सर्ट्रालिन लेबल, दवाओं के इंटरैक्शन)

  • साइक्लोबेंज़ाप्रिनमसल रिलैक्सेंटगंभीर

    Based on its structural similarity to TCAs, concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the… (साइक्लोबेंज़ाप्रिन लेबल, दवाओं के इंटरैक्शन)

  • सिप्रोफ्लॉक्सासिनफ्लुओरोक्विनोलोनगंभीर

    Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (सिप्रोफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

  • सेटिरिज़िनएंटीहिस्टामिनगंभीर

    Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (सेटिरिज़िन लेबल, चेतावनियां और सावधानियां)

  • सोडियम ऑक्सीबेटCNS डिप्रेसेंटगंभीर

    • Central Nervous System Depression Xyrem (sodium oxybate) is a CNS depressant. (सोडियम ऑक्सीबेट लेबल, बॉक्स्ड चेतावनी)

  • हाइड्रॉक्सीक्लोरोक्वीनQT अंतराल बढ़ाने वाली दवागंभीर

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (हाइड्रॉक्सीक्लोरोक्वीन लेबल, चेतावनियां और सावधानियां)

  • हाइड्रॉक्सीज़िनएंटीहिस्टामिनगंभीर

    Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. (हाइड्रॉक्सीज़िन लेबल, सावधानियां)

  • हाइड्रोकोडोनओपिओइडगंभीर

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन लेबल, बॉक्स्ड चेतावनी)

  • …LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P4503A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE AND IBUPROFEN TABLETS Addiction,… (हाइड्रोकोडोन और आइबुप्रोफेन लेबल, बॉक्स्ड चेतावनी)

  • …ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION;… (हाइड्रोकोडोन और क्लोरफेनिरामिन लेबल, बॉक्स्ड चेतावनी)

  • Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

  • …ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Hydrocodone bitartrate and homatropine methylbromide exposes patients and… (हाइड्रोकोडोन और होमाट्रोपिन लेबल, बॉक्स्ड चेतावनी)

  • हाइड्रोमॉर्फोनओपिओइडगंभीर

    Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death . (हाइड्रोमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

मध्यम इंटरैक्शन (249)

  • आइसोफ्लुरेनजनरल एनेस्थेटिकमध्यम

    Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (आइसोफ्लुरेन लेबल, चेतावनियां और सावधानियां)

  • Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • आरफॉर्मोटेरोलबीटा-एड्रीनर्जिक एगोनिस्टमध्यम

    MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (आरफॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

  • आर्मोडाफिनिलCNS स्टिमुलेंटमध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • इंडापामाइडथायज़ाइड डाइयूरेटिकमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • इंसुलिन एस्पार्टइंसुलिनमध्यम

    Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (इंसुलिन एस्पार्ट लेबल, दवाओं के इंटरैक्शन)

  • इंसुलिन ग्लार्जिनइंसुलिनमध्यम

    Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents… (इंसुलिन ग्लार्जिन लेबल, दवाओं के इंटरैक्शन)

  • इंसुलिन डेग्लुडेकइंसुलिनमध्यम

    Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (इंसुलिन डेग्लुडेक लेबल, दवाओं के इंटरैक्शन)

  • इंसुलिन डेटेमिरइंसुलिनमध्यम

    Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (इंसुलिन डेटेमिर लेबल, दवाओं के इंटरैक्शन)

  • इंसुलिन लिस्प्रोइंसुलिनमध्यम

    Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (इंसुलिन लिस्प्रो लेबल, दवाओं के इंटरैक्शन)

  • इट्राकोनाज़ोलएज़ोल एंटीफंगलमध्यम

    Antipsychotics, Anxiolytics and Hypnotics Alprazolam Aripiprazole Buspirone Diazepam Haloperidol Midazolam (IV) Quetiapine Ramelteon Risperidone Suvorexant Monitor for adverse reactions. (इट्राकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

  • इमिप्रामिनट्राइसाइक्लिक एंटीडिप्रेसेंटमध्यम

    Imipramine hydrochloride may enhance the CNS depressant effects of alcohol. (इमिप्रामिन लेबल, चेतावनियां)

  • इमैटिनिबCYP3A4 इनहिबिटरमध्यम

    Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • इर्बेसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • इर्बेसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • इसराडिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • एज़िलसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • एटेनोलोलबीटा ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • एटेनोलोल और क्लोरथैलिडोनबीटा ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • एट्राविरिनएंटीरेट्रोवायरलमध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • एथाक्रिनिक एसिडलूप डाइयूरेटिकमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • एनालाप्रिलACE इनहिबिटरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • एनालाप्रिलैटACE इनहिबिटरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • एप्रेपिटेंटCYP3A4 इनहिबिटरमध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • एप्लेरेनोनएल्डोस्टेरोन एंटागोनिस्टमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • एफाविरेंज़एंटीरेट्रोवायरलमध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • एबिराटेरोनCYP2D6 इनहिबिटरमध्यम

    Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • एमिनोफाइलिनमिथाइलज़ैंथिनमध्यम

    25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (एमिनोफाइलिन लेबल, दवाओं के इंटरैक्शन)

  • एमिलोराइडपोटैशियम-स्पेयरिंग डाइयूरेटिकमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • एम्लोडिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • एम्लोडिपिन और एटोरवास्टेटिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • एम्लोडिपिन और ओल्मेसार्टनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • एम्लोडिपिन और बेनाज़ेप्रिलडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • एम्लोडिपिन और वाल्सार्टनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • एरिपिप्राज़ोलएंटीसाइकोटिकमध्यम

    RISPERDAL CONSTA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. [see also Boxed Warning and Warnings and Precautions (5.1) ] 5.13 Priapism Priapism has been reported during postmarketing surveillance [see Adverse Reactions (6.2) ] . (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (एरिबुलिन लेबल, चेतावनियां और सावधानियां)

  • एलिस्किरेनएंटीहाइपरटेंसिव (ब्लड प्रेशर की दवा)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • एलोप्यूरिनॉलज़ैंथिन ऑक्सीडेज़ इनहिबिटरमध्यम

    Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (एलोप्यूरिनॉल लेबल, चेतावनियां और सावधानियां)

  • एवरोलिमसइम्यूनोसप्रेसेंटमध्यम

    Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • एसिब्यूटोलोलबीटा ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • एस्लिकार्बाज़ेपिनएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • ऑक्सकार्बाज़ेपिनएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • ओलैंज़ापिनएंटीसाइकोटिकमध्यम

    RISPERDAL CONSTA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. [see also Boxed Warning and Warnings and Precautions (5.1) ] 5.13 Priapism Priapism has been reported during postmarketing surveillance [see Adverse Reactions (6.2) ] . (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • ओलैंज़ापिन और फ्लुओक्सेटिनएंटीसाइकोटिकमध्यम

    Fluoxetine and paroxetine increase plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • ओल्मेसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • ओल्मेसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • ओल्मेसार्टन, एम्लोडिपिन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • Dopamine D 2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa. (कार्बिडोपा लेबल, दवाओं के इंटरैक्शन)

  • कार्बिडोपा और लेवोडोपाडोपामिनर्जिक दवामध्यम

    Dopamine D2 Receptor Antagonists and Isoniazid Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone, metoclopramide, papaverine) and isoniazid may reduce the effectiveness of levodopa. (कार्बिडोपा और लेवोडोपा लेबल, दवाओं के इंटरैक्शन)

  • कार्बिडोपा, लेवोडोपा और एंटाकैपोनडोपामिनर्जिक दवामध्यम

    Dopamine D2 Receptor Antagonists Dopamine D2 receptor antagonists (e.g., metoclopramide, phenothiazines, butyrophenones, risperidone) may reduce the therapeutic effects of levodopa. (कार्बिडोपा, लेवोडोपा और एंटाकैपोन लेबल, दवाओं के इंटरैक्शन)

  • कार्वेडिलोलबीटा ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • कैंडेसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • कैंडेसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • कैनाबिडियोल (प्रिस्क्रिप्शन दवा)एंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    Other CNS depressants, including alcohol, could potentiate the somnolence and sedation effect of EPIDIOLEX. (कैनाबिडियोल (प्रिस्क्रिप्शन दवा) लेबल, चेतावनियां और सावधानियां)

  • कैप्टोप्रिलACE इनहिबिटरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • कैरिसोप्रोडोलमसल रिलैक्सेंटमध्यम

    • Additive sedative effects when used with other CNS depressants including alcohol (5.1) (कैरिसोप्रोडोल लेबल, चेतावनियां और सावधानियां)

  • क्लेमास्टिनएंटीहिस्टामिनमध्यम

    Use with CNS Depressants Clemastine has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). Use in Activities Requiring Mental Alertness Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc. (क्लेमास्टिन लेबल, चेतावनियां)

  • क्लोज़ापिनएंटीसाइकोटिकमध्यम

    Clozapine may decrease clearance of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • क्लोरज़ोक्साज़ोनमसल रिलैक्सेंटमध्यम

    Chlorzoxazone use should also be discontinued if a patient develops abnormal liver enzymes (e.g., AST, ALT, alkaline phosphatase and bilirubin.) The concomitant use of alcohol or other central nervous system depressants may have an additive effect. (क्लोरज़ोक्साज़ोन लेबल, चेतावनियां और सावधानियां)

  • क्लोरथैलिडोनथायज़ाइड डाइयूरेटिकमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • क्लोरप्रोमाज़िनएंटीसाइकोटिकमध्यम

    RISPERDAL CONSTA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. [see also Boxed Warning and Warnings and Precautions (5.1) ] 5.13 Priapism Priapism has been reported during postmarketing surveillance [see Adverse Reactions (6.2) ] . (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • क्लोरोथायज़ाइडथायज़ाइड डाइयूरेटिकमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • क्विनाप्रिलACE इनहिबिटरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • क्विनिडिनएंटीएरिदमिकमध्यम

    Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (गोसेरेलिन लेबल, चेतावनियां और सावधानियां)

  • ग्रिसियोफुल्विनएंटीफंगलमध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • ग्लिपिज़ाइडसल्फोनिलयूरियामध्यम

    The following are examples of medication that may reduce the glucose-lowering effect of GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease… (ग्लिपिज़ाइड लेबल, दवाओं के इंटरैक्शन)

  • ग्लिमेपिराइडसल्फोनिलयूरियामध्यम

    …medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid… (ग्लिमेपिराइड लेबल, दवाओं के इंटरैक्शन)

  • ग्वानफेसिनअल्फा-एड्रीनर्जिक एगोनिस्टमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • ज़ोनिसामाइडएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    Patients should be carefully observed for signs of central nervous system (CNS) depression, such as somnolence and sedation, when ZONISADE is used with other drugs with sedative properties because of potential additive effects. (ज़ोनिसामाइड लेबल, चेतावनियां और सावधानियां)

  • टर्बिनाफिनएंटीफंगलमध्यम

    Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • टिज़ानिडिनमसल रिलैक्सेंटमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • टेराज़ोसिनअल्फा ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • टेल्मिसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • टेल्मिसार्टन और एम्लोडिपिनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • टेल्मिसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • टॉरसेमाइडलूप डाइयूरेटिकमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • टोपिरामेटएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    Topiramate Oral RISPERDAL administered at doses from 1–6 mg/day concomitantly with topiramate 400 mg/day resulted in a 23% decrease in risperidone C max and a 33% decrease in risperidone AUC 0–12 hour at steady state. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • टोरेमिफेनसेलेक्टिव एस्ट्रोजन रिसेप्टर मॉड्यूलेटरमध्यम

    …accepted to prolong QT interval include Class 1A (e.g., quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin,… (टोरेमिफेन लेबल, दवाओं के इंटरैक्शन)

  • Hyperpyrexia and Confusion: In clinical trials, four cases of a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, and altered consciousness), similar to that reported in association with the rapid dose reduction or withdrawal of other dopaminergic drugs, have been reported in association with… (टोलकैपोन लेबल, सावधानियां)

  • ट्राइफ्लुओपेराज़िनएंटीसाइकोटिकमध्यम

    RISPERDAL CONSTA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. [see also Boxed Warning and Warnings and Precautions (5.1) ] 5.13 Priapism Priapism has been reported during postmarketing surveillance [see Adverse Reactions (6.2) ] . (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • ट्रायमटेरिनपोटैशियम-स्पेयरिंग डाइयूरेटिकमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • ट्रायमटेरिन और हाइड्रोक्लोरोथायज़ाइडपोटैशियम-स्पेयरिंग डाइयूरेटिकमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (ट्रिप्टोरेलिन लेबल, चेतावनियां और सावधानियां)

  • ट्रैंडोलाप्रिलACE इनहिबिटरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • ट्रैज़ोडोनएंटीडिप्रेसेंटमध्यम

    …are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

  • ट्रैनिलसाइप्रोमिनMAO इनहिबिटरमध्यम

    Excessive reduction of blood glucose (additive effect) f CNS depressant agents (including opioids, alcohol, sedatives, hypnotics) Use with caution d Increased CNS depression Dietary supplements containing sympathomimetics Contraindicated a Antidepressants including but not limited to: Other MAOIs (e.g., linezolid, intravenous methylene blue, selective MAOIs)… (ट्रैनिलसाइप्रोमिन लेबल, दवाओं के इंटरैक्शन)

  • डाइफेनहाइड्रामिनएंटीहिस्टामिनमध्यम

    Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • डाइमेनहाइड्रिनेटएंटीहिस्टामिनमध्यम

    The concomitant use of alcohol or other central nervous system depressants may have an additive effect. (डाइमेनहाइड्रिनेट लेबल, चेतावनियां)

  • डाइसाइक्लोमिनएंटीकोलिनर्जिकमध्यम

    …increase certain actions or side effects of anticholinergic drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants,… (डाइसाइक्लोमिन लेबल, दवाओं के इंटरैक्शन)

  • डिल्टियाज़ेमकैल्शियम चैनल ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • डेक्सक्लोरफेनिरामिनएंटीहिस्टामिनमध्यम

    Use with CNS Depressants CORPHENA Oral Solution has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). Use in Activities Requiring Mental Alertness Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc. (डेक्सक्लोरफेनिरामिन लेबल, चेतावनियां)

  • डेक्सट्रोमेथॉर्फन और क्विनिडिनसेरोटोनर्जिक दवामध्यम

    Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • डेक्समिथाइलफेनिडेटCNS स्टिमुलेंटमध्यम

    Risperidone Clinical impact Combined use of methylphenidate with risperidone when there is a change, whether an increase or decrease, in dosage of either or both medications, may increase the risk of extrapyramidal symptoms (EPS) Intervention Monitor for signs of EPS (डेक्समिथाइलफेनिडेट लेबल, दवाओं के इंटरैक्शन)

  • डेक्सामेथासोनकॉर्टिकोस्टेरॉइडमध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • डेफेरासिरोक्सआयरन सप्लीमेंटमध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • डेसफ्लुरेनजनरल एनेस्थेटिकमध्यम

    Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (डेसफ्लुरेन लेबल, चेतावनियां और सावधानियां)

  • डैंट्रोलीनमसल रिलैक्सेंटमध्यम

    Antipsychotics and Antianxiety Agents The concomitant administration of RYANODEX with antipsychotic and antianxiety agents may potentiate their effects on the central nervous system [see Warnings and Precautions ( 5.2 )] . (डैंट्रोलीन लेबल, दवाओं के इंटरैक्शन)

  • डैरिडोरेक्सेंटसेडेटिव-हिप्नोटिक (नींद की दवा)मध्यम

    CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (डैरिडोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

  • डैरिफेनासिनएंटीकोलिनर्जिकमध्यम

    Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • डॉक्साज़ोसिनअल्फा ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • डॉक्सेपिनट्राइसाइक्लिक एंटीडिप्रेसेंटमध्यम

    Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (डॉक्सेपिन लेबल, चेतावनियां और सावधानियां)

  • ड्रॉक्सीडोपासिम्पैथोमिमेटिकमध्यम

    Observe patients carefully when the dosage of NORTHERA is changed or when concomitant levodopa is reduced abruptly or discontinued, especially if the patient is receiving neuroleptics. (ड्रॉक्सीडोपा लेबल, चेतावनियां और सावधानियां)

  • ड्रोनाबिनोलकैनाबिनॉइडमध्यम

    Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (ड्रोनाबिनोल लेबल, चेतावनियां और सावधानियां)

  • ड्रोपेरिडोलडोपामिन एंटागोनिस्टमध्यम

    …cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs… (ड्रोपेरिडोल लेबल, चेतावनियां)

  • थायोथिक्सीनएंटीसाइकोटिकमध्यम

    RISPERDAL CONSTA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. [see also Boxed Warning and Warnings and Precautions (5.1) ] 5.13 Priapism Priapism has been reported during postmarketing surveillance [see Adverse Reactions (6.2) ] . (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • थियोफाइलिनमिथाइलज़ैंथिनमध्यम

    25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (थियोफाइलिन लेबल, दवाओं के इंटरैक्शन)

  • नाइट्रोप्रुसाइडवैसोडाइलेटरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • नाडोलोलबीटा ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • नालोक्सोनओपिओइड एंटागोनिस्टमध्यम

    WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (नालोक्सोन लेबल, चेतावनियां और सावधानियां)

  • नाल्ट्रेक्सोन और ब्यूप्रोपियॉनओपिओइड एंटागोनिस्टमध्यम

    Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • निकार्डिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • निफेडिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • निलोटिनिबQT अंतराल बढ़ाने वाली दवामध्यम

    Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • निसोल्डिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • नेबिवोलोलबीटा ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • नेविरापिनएंटीरेट्रोवायरलमध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • नैफसिलिनपेनिसिलिन एंटीबायोटिकमध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • परफेनाज़िनएंटीसाइकोटिकमध्यम

    RISPERDAL CONSTA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. [see also Boxed Warning and Warnings and Precautions (5.1) ] 5.13 Priapism Priapism has been reported during postmarketing surveillance [see Adverse Reactions (6.2) ] . (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • पिंडोलोलबीटा ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • पिमावैनसेरिनएंटीसाइकोटिकमध्यम

    RISPERDAL CONSTA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. [see also Boxed Warning and Warnings and Precautions (5.1) ] 5.13 Priapism Priapism has been reported during postmarketing surveillance [see Adverse Reactions (6.2) ] . (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • पियोग्लिटाज़ोन और ग्लिमेपिराइडथायज़ोलिडिनडायोनमध्यम

    …medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid… (पियोग्लिटाज़ोन और ग्लिमेपिराइड लेबल, दवाओं के इंटरैक्शन)

  • पेरिंडोप्रिलACE इनहिबिटरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • पेरैम्पेनलएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    Patients should be carefully observed for signs of central nervous system (CNS) depression, such as somnolence and sedation, when FYCOMPA is used with other drugs with sedative properties because of potential additive effects. (पेरैम्पेनल लेबल, चेतावनियां और सावधानियां)

  • Fluoxetine and paroxetine increase plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (पैसिरियोटाइड लेबल, दवाओं के इंटरैक्शन)

  • पोनेसिमोडइम्यूनोसप्रेसेंटमध्यम

    Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (पोनेसिमोड लेबल, दवाओं के इंटरैक्शन)

  • पोसाकोनाज़ोलएज़ोल एंटीफंगलमध्यम

    Concomitant Use with Midazolam : Noxafil can prolong hypnotic/sedative effects. (पोसाकोनाज़ोल लेबल, चेतावनियां और सावधानियां)

  • प्राइमाक्वीनमलेरिया-रोधी दवामध्यम

    QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (प्राइमाक्वीन लेबल, दवाओं के इंटरैक्शन)

  • प्राज़ोसिनअल्फा ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • प्रिमिडोनएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • प्रैमिपेक्सोलडोपामिन एगोनिस्टमध्यम

    Hyperpyrexia and Confusion Although not reported with pramipexole in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction,… (प्रैमिपेक्सोल लेबल, चेतावनियां और सावधानियां)

  • प्रोक्लोरपेराज़िनएंटीसाइकोटिकमध्यम

    RISPERDAL CONSTA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. [see also Boxed Warning and Warnings and Precautions (5.1) ] 5.13 Priapism Priapism has been reported during postmarketing surveillance [see Adverse Reactions (6.2) ] . (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • प्रोट्रिप्टिलीनट्राइसाइक्लिक एंटीडिप्रेसेंटमध्यम

    Protriptyline may enhance the response to alcohol and the effects of barbiturates and other CNS depressants. (प्रोट्रिप्टिलीन लेबल, दवाओं के इंटरैक्शन)

  • प्रोपोफोलCNS डिप्रेसेंटमध्यम

    As with other sedative medications, there is wide interpatient variability in DIPRIVAN dosage requirements, and these requirements may change with time. (प्रोपोफोल लेबल, चेतावनियां और सावधानियां)

  • प्रोप्रानोलोलबीटा ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • प्रोमेथाज़िनएंटीहिस्टामिनमध्यम

    The impairment may be amplified by concomitant use of other central-nervous-system depressants such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore such agents should either be eliminated or given in reduced dosage in the presence of promethazine… (प्रोमेथाज़िन लेबल, चेतावनियां)

  • The impairment may be amplified by concomitant use of other central-nervous-system depressants such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore such agents should either be eliminated or given in reduced dosage in the presence of promethazine… (प्रोमेथाज़िन और डेक्सट्रोमेथॉर्फन लेबल, चेतावनियां)

  • फेंटरमिन और टोपिरामेटCNS स्टिमुलेंटमध्यम

    Topiramate Oral RISPERDAL administered at doses from 1–6 mg/day concomitantly with topiramate 400 mg/day resulted in a 23% decrease in risperidone C max and a 33% decrease in risperidone AUC 0–12 hour at steady state. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • फेनिटोइनएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • फेनोक्सीबेंज़ामिनअल्फा ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • Co-administration of other known CYP 3A4 enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of RISPERDAL CONSTA treatment. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • फेलोडिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • फॉर्मोटेरोलबीटा-एड्रीनर्जिक एगोनिस्टमध्यम

    …Antidepressants, QTc Prolonging Drugs Formoterol, as with other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (फॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

  • फॉस्फेनिटोइनएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • फोसिनोप्रिलACE इनहिबिटरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • फ्यूरोसेमाइडलूप डाइयूरेटिकमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • फ्लिबैनसेरिनCNS डिप्रेसेंटमध्यम

    Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (फ्लिबैनसेरिन लेबल, चेतावनियां और सावधानियां)

  • Fluoxetine and paroxetine increase plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • फ्लुफेनाज़िनएंटीसाइकोटिकमध्यम

    RISPERDAL CONSTA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. [see also Boxed Warning and Warnings and Precautions (5.1) ] 5.13 Priapism Priapism has been reported during postmarketing surveillance [see Adverse Reactions (6.2) ] . (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • फ्लुमाज़ेनिलबेंज़ोडायज़ेपिनमध्यम

    Possible risk factors for seizures include: concurrent major sedative-hypnotic drug withdrawal, recent therapy with repeated doses of parenteral benzodiazepines, myoclonic jerking or seizure activity prior to flumazenil administration in overdose cases, or concurrent cyclic antidepressant poisoning. (फ्लुमाज़ेनिल लेबल, चेतावनियां)

  • CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

  • बस्पिरोनसेरोटोनर्जिक दवामध्यम

    Triazolam/flurazepam: Coadministration of buspirone with either triazolam or flurazepam did not appear to prolong or intensify the sedative effects of either benzodiazepine. (बस्पिरोन लेबल, दवाओं के इंटरैक्शन)

  • Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO. (बिक्टेग्राविर, एमट्रिसिटाबिन और टेनोफोविर एलाफेनामाइड लेबल, दवाओं के इंटरैक्शन)

  • बिसोप्रोलोलबीटा ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (बिस्मथ सबसाइट्रेट, मेट्रोनिडाज़ोल और टेट्रासाइक्लिन लेबल, चेतावनियां और सावधानियां)

  • बीटाक्सोलोलबीटा ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • बेनाज़ेप्रिलACE इनहिबिटरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • बैक्लोफेनमसल रिलैक्सेंटमध्यम

    Patients should also be cautioned that the central nervous system depressant effects of intrathecal baclofen may be additive to those of alcohol and other CNS depressants. (बैक्लोफेन लेबल, चेतावनियां और सावधानियां)

  • बोसेंटनCYP3A4 इंड्यूसरमध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • ब्यूटाल्बिटल और पैरासिटामोलबार्बिट्यूरेटमध्यम

    Butalbital and acetaminophen may enhance the effects of:other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. (ब्यूटाल्बिटल और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

  • Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. (ब्यूटाल्बिटल, एस्पिरिन और कैफीन लेबल, दवाओं के इंटरैक्शन)

  • Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. (ब्यूटाल्बिटल, पैरासिटामोल और कैफीन लेबल, दवाओं के इंटरैक्शन)

  • ब्यूपिवाकेनलोकल एनेस्थेटिकमध्यम

    Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (ब्यूपिवाकेन लेबल, चेतावनियां और सावधानियां)

  • ब्यूपिवाकेन और एड्रेनालिनलोकल एनेस्थेटिकमध्यम

    Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (ब्यूपिवाकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

  • Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with buprenorphine and naloxone sublingual tablets [see Warnings and Precautions (5.3) , Drug Interactions (7) ] . (ब्यूप्रेनॉर्फिन और नालोक्सोन लेबल, चेतावनियां और सावधानियां)

  • ब्यूप्रोपियॉनएंटीडिप्रेसेंटमध्यम

    Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • ब्रिमोनिडिनअल्फा-एड्रीनर्जिक एगोनिस्टमध्यम

    Use with CNS depressants may result in an additive or potentiating effect. (ब्रिमोनिडिन लेबल, दवाओं के इंटरैक्शन)

  • ब्रिमोनिडिन और टिमोलोलअल्फा-एड्रीनर्जिक एगोनिस्टमध्यम

    Use with CNS depressants may result in an additive or potentiating effect. (ब्रिमोनिडिन और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

  • Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (ब्रोमफेनिरामिन, स्यूडोएफेड्रिन और डेक्सट्रोमेथॉर्फन लेबल, दवाओं के इंटरैक्शन)

  • माइटोटेनCYP3A4 इंड्यूसरमध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • मिटापिवैटCYP3A4 इंड्यूसरमध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • मिथाइलडोपाएंटीहाइपरटेंसिव (ब्लड प्रेशर की दवा)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • मिथाइलफेनिडेटCNS स्टिमुलेंटमध्यम

    Methylphenidate Concomitant use with methylphenidate, when there is change in dosage of either medication, may increase the risk of extrapyramidal symptoms (EPS). (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • मिनोक्सिडिलवैसोडाइलेटरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • मिफेप्रिस्टोनCYP3A4 इनहिबिटरमध्यम

    There is little or no experience with high exposure, concomitant dosing with other QT-prolonging drugs, or potassium channel variants resulting in a long QT interval. [See Warnings & Precautions ( 5.6 )] To minimize risk, the lowest effective dose should always be used. (मिफेप्रिस्टोन लेबल, चेतावनियां और सावधानियां)

  • मिराबेग्रॉनबीटा-एड्रीनर्जिक एगोनिस्टमध्यम

    Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • मेकामाइलामिनएंटीहाइपरटेंसिव (ब्लड प्रेशर की दवा)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • मेक्लिज़िनएंटीहिस्टामिनमध्यम

    • Coadministration of meclizine hydrochloride with other CNS depressants, including alcohol, may result in increased CNS depression ( 7.1 ). (मेक्लिज़िन लेबल, दवाओं के इंटरैक्शन)

  • Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (मेटाइरोसिन लेबल, दवाओं के इंटरैक्शन)

  • मेटोप्रोलोलबीटा ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • मेटोलाज़ोनथायज़ाइड डाइयूरेटिकमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • मेट्रोनिडाज़ोलएंटीबायोटिकमध्यम

    Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (मेट्रोनिडाज़ोल लेबल, दवाओं के इंटरैक्शन)

  • मेथस्कोपोलामाइनएंटीकोलिनर्जिकमध्यम

    Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. (मेथस्कोपोलामाइन लेबल, दवाओं के इंटरैक्शन)

  • मेथोकार्बामोलमसल रिलैक्सेंटमध्यम

    CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

  • मेथोहेक्सिटलबार्बिट्यूरेटमध्यम

    The CNS-depressant effect of BREVITAL may be additive with that of other CNS depressants, including ethyl alcohol and propylene glycol. (मेथोहेक्सिटल लेबल, चेतावनियां)

  • मेप्रोबामेटCNS डिप्रेसेंटमध्यम

    Additive Effects Since the effects of meprobamate and alcohol or meprobamate and other CNS depressants or psychotropic drugs may be additive,appropriate caution should be exercised with patients who take more than one of these agents simultaneously. (मेप्रोबामेट लेबल, चेतावनियां)

  • मेफ्लोक्वीनमलेरिया-रोधी दवामध्यम

    Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (मेफ्लोक्वीन लेबल, दवाओं के इंटरैक्शन)

  • मॉक्सीफ्लॉक्सासिनफ्लुओरोक्विनोलोनमध्यम

    Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (मॉक्सीफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

  • मोएक्सिप्रिलACE इनहिबिटरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • मोडाफिनिलCNS स्टिमुलेंटमध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • यूमेक्लिडिनियम और विलैंटेरोलएंटीकोलिनर्जिकमध्यम

    …like other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval or within 2 weeks of discontinuation of such agents, because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (यूमेक्लिडिनियम और विलैंटेरोल लेबल, दवाओं के इंटरैक्शन)

  • रासाजिलिनMAO इनहिबिटरमध्यम

    Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (रासाजिलिन लेबल, चेतावनियां और सावधानियां)

  • रिफापेंटिनएंटीबायोटिकमध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • रिफाब्यूटिनएंटीबायोटिकमध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • रिल्पिविरिनएंटीरेट्रोवायरलमध्यम

    In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (रिल्पिविरिन लेबल, चेतावनियां और सावधानियां)

  • रैनिटिडीनH2 ब्लॉकरमध्यम

    Cimetidine and ranitidine increase the bioavailability of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • रैनोलाज़िनQT अंतराल बढ़ाने वाली दवामध्यम

    Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • रैमिप्रिलACE इनहिबिटरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • रैमेल्टियॉनसेडेटिव-हिप्नोटिक (नींद की दवा)मध्यम

    The use of alcohol and other CNS depressants may increase the risk of such behaviors. (रैमेल्टियॉन लेबल, चेतावनियां और सावधानियां)

  • रोक्यूरोनियमन्यूरोमस्कुलर ब्लॉकरमध्यम

    QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (रोक्यूरोनियम लेबल, चेतावनियां और सावधानियां)

  • रोपिनिरोलडोपामिन एगोनिस्टमध्यम

    Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction of, withdrawal of, or changes in, dopaminergic therapy. (रोपिनिरोल लेबल, चेतावनियां और सावधानियां)

  • रोलापिटेंटCYP2D6 इनहिबिटरमध्यम

    Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • लिडोकेन और एड्रेनालिनलोकल एनेस्थेटिकमध्यम

    Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (लिडोकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

  • लिथियमसेरोटोनर्जिक दवामध्यम

    • Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (लिथियम लेबल, चेतावनियां और सावधानियां)

  • लिसिनोप्रिलACE इनहिबिटरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • लेबेटालोलबीटा ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • लेम्बोरेक्सेंटसेडेटिव-हिप्नोटिक (नींद की दवा)मध्यम

    CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

  • लेवोडोपाडोपामिनर्जिक दवामध्यम

    Dopamine D2 Receptor Antagonists and Isoniazid Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone, metoclopramide) and isoniazid may reduce the effectiveness of levodopa. (लेवोडोपा लेबल, दवाओं के इंटरैक्शन)

  • लैपाटिनिबP-ग्लाइकोप्रोटीन इनहिबिटरमध्यम

    TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

  • लोक्सापिनएंटीसाइकोटिकमध्यम

    RISPERDAL CONSTA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. [see also Boxed Warning and Warnings and Precautions (5.1) ] 5.13 Priapism Priapism has been reported during postmarketing surveillance [see Adverse Reactions (6.2) ] . (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • लोपेरामाइडQT अंतराल बढ़ाने वाली दवामध्यम

    …others drugs or herbal products that are known to prolong the QT interval, including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, antipsychotics (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), or any other drug known to prolong the QT interval (e.g., pentamidine,… (लोपेरामाइड लेबल, चेतावनियां)

  • लोफेक्सिडिनअल्फा-एड्रीनर्जिक एगोनिस्टमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • लोरलाटिनिबCYP3A4 इंड्यूसरमध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • लोसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • लोसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (ल्यूप्रोलाइड लेबल, चेतावनियां और सावधानियां)

  • वाल्सार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • वाल्सार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC. (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

  • वेरापामिलकैल्शियम चैनल ब्लॉकरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • वोरिकोनाज़ोलएज़ोल एंटीफंगलमध्यम

    Eszopiclone (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased which may Increase the Sedative Effect of Eszopiclone Dose reduction of eszopiclone is recommended. (वोरिकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

  • साइप्रोहेप्टाडीनएंटीहिस्टामिनमध्यम

    CNS Depressants Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents. (साइप्रोहेप्टाडीन लेबल, चेतावनियां)

  • Avoid use of Citalopram Capsules in patients with congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure and patients taking other drugs that prolong the QTc interval. (सिटालोप्राम लेबल, चेतावनियां और सावधानियां)

  • सिनाकैल्सेटCYP2D6 इनहिबिटरमध्यम

    Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • सिमेटिडीनH2 ब्लॉकरमध्यम

    Cimetidine and ranitidine increase the bioavailability of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • सुज़ेट्रिजिनCYP3A4 इंड्यूसरमध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (सुनिटिनिब लेबल, दवाओं के इंटरैक्शन)

  • सुवोरेक्सेंटसेडेटिव-हिप्नोटिक (नींद की दवा)मध्यम

    CNS Depressant Effects and Daytime Impairment: Risk of impaired alertness and motor coordination, including impaired driving; risk increases with dose; caution patients taking 20 mg against next-day driving and other activities requiring complete mental alertness ( 5.1 ). (सुवोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

  • सेनोबामेटएंटीकन्वल्सेंट (दौरे की दवा)मध्यम

    Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • सेलेजिलिनMAO इनहिबिटरमध्यम

    Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (सेलेजिलिन लेबल, चेतावनियां और सावधानियां)

  • सेवोफ्लुरेनजनरल एनेस्थेटिकमध्यम

    Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (सेवोफ्लुरेन लेबल, चेतावनियां)

  • सैक्यूबिट्रिल और वाल्सार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • सोटालोलबीटा ब्लॉकरमध्यम

    Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (सोटालोल लेबल, दवाओं के इंटरैक्शन)

  • Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (सोराफेनिब लेबल, चेतावनियां और सावधानियां)

  • स्पिरोनोलैक्टोनएल्डोस्टेरोन एंटागोनिस्टमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • स्पिरोनोलैक्टोन और हाइड्रोक्लोरोथायज़ाइडएल्डोस्टेरोन एंटागोनिस्टमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • हाइड्रालाज़िनवैसोडाइलेटरमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • हाइड्रोक्लोरोथायज़ाइडथायज़ाइड डाइयूरेटिकमध्यम

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

  • हेलोपेरिडोलएंटीसाइकोटिकमध्यम

    RISPERDAL CONSTA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. [see also Boxed Warning and Warnings and Precautions (5.1) ] 5.13 Priapism Priapism has been reported during postmarketing surveillance [see Adverse Reactions (6.2) ] . (रिस्पेरिडोन लेबल, चेतावनियां और सावधानियां)

मामूली ज़िक्र (15)

  • अमैंटाडिनएंटीकोलिनर्जिकमामूली

    Effects of levodopa and dopamine agonists may be antagonized. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • एटोमोक्सेटिननॉरएपिनेफ्रिन रीअपटेक इनहिबिटरमामूली

    Some cases presented with features resembling neuroleptic malignant syndrome. (एटोमोक्सेटिन लेबल, दवाओं के इंटरैक्शन)

  • The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (एपोएटिन अल्फा लेबल, चेतावनियां और सावधानियां)

  • एमिट्रिप्टिलीनट्राइसाइक्लिक एंटीडिप्रेसेंटमामूली

    Guanethidine or similarly acting compounds; thyroid medication; alcohol, barbiturates and other CNS depressants; and disulfiram – see WARNINGS section. (एमिट्रिप्टिलीन लेबल, दवाओं के इंटरैक्शन)

  • कैबरगोलिनडोपामिन एगोनिस्टमामूली

    Effects of levodopa and dopamine agonists may be antagonized. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • ग्रैनिसेट्रॉनQT अंतराल बढ़ाने वाली दवामामूली

    There have been no definitive drug-drug interaction studies to examine pharmacokinetic or pharmacodynamic interaction with other drugs; however, in humans, granisetron hydrochloride injection has been safely administered with drugs representing benzodiazepines, neuroleptics and anti-ulcer medications commonly prescribed with antiemetic treatments. (ग्रैनिसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

  • ग्लाइकोपाइरोलेटएंटीकोलिनर्जिकमामूली

    Co-administration of antipsychotics with glycopyrrolate may lead to worsening of tardive dyskinesia. (ग्लाइकोपाइरोलेट लेबल, दवाओं के इंटरैक्शन)

  • टियागाबिनएंटीकन्वल्सेंट (दौरे की दवा)मामूली

    In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (टियागाबिन लेबल, चेतावनियां)

  • डिगॉक्सिनडिजिटेलिस ग्लाइकोसाइडमामूली

    Digoxin Oral RISPERDAL (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • डेक्सट्रोएम्फेटामाइनCNS स्टिमुलेंटमामूली

    Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

  • In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (डॉक्साप्राम लेबल, चेतावनियां)

  • नेफाज़ोडोनएंटीडिप्रेसेंटमामूली

    Some cases presented with features resembling neuroleptic malignant syndrome. (नेफाज़ोडोन लेबल, चेतावनियां)

  • बेंज़ट्रोपिनएंटीकोलिनर्जिकमामूली

    Drug Interactions Antipsychotic drugs such as phenothiazines or haloperidol; tricyclic antidepressants [ see WARNINGS ]. (बेंज़ट्रोपिन लेबल, दवाओं के इंटरैक्शन)

  • Atypical Antipsychotics (e.g., olanzapine and clozapine), Corticosteroids, Danazol, Diuretics, Estrogens, Glucagon, Isoniazid, Niacin, Oral Contraceptives, Phenothiazines, Progestogens (e.g., in oral contraceptives), Protease inhibitors, Somatropin, Sympathomimetic Agents (e.g., albuterol, epinephrine, terbutaline) and Thyroid Hormones. (रेगुलर इंसुलिन (ह्यूमन) लेबल, दवाओं के इंटरैक्शन)

  • रेपाग्लिनाइडमेग्लिटिनाइडमामूली

    Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (रेपाग्लिनाइड लेबल, दवाओं के इंटरैक्शन)

कोई महत्वपूर्ण इंटरैक्शन नहीं बताया गया (6)

  • एरिथ्रोमाइसिनमैक्रोलाइड एंटीबायोटिककोई इंटरैक्शन नहीं

    Erythromycin There were no significant interactions between oral RISPERDAL and erythromycin. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • गैलेंटामिनकोलिनेस्टेरेज़ इनहिबिटरकोई इंटरैक्शन नहीं

    In drug interaction studies, oral RISPERDAL did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • डोनेपेज़िलकोलिनेस्टेरेज़ इनहिबिटरकोई इंटरैक्शन नहीं

    In drug interaction studies, oral RISPERDAL did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • मेमेंटिन और डोनेपेज़िलकोलिनेस्टेरेज़ इनहिबिटरकोई इंटरैक्शन नहीं

    In drug interaction studies, oral RISPERDAL did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

  • मोंटेलुकास्टल्यूकोट्राइन रिसेप्टर एंटागोनिस्टकोई इंटरैक्शन नहीं

    …adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (मोंटेलुकास्ट लेबल, दवाओं के इंटरैक्शन)

  • लेनाकैपाविरएंटीरेट्रोवायरलकोई इंटरैक्शन नहीं

    Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use with caution when midazolam or triazolam is concomitantly administered with SUNLENCA 7.4 Drugs without Clinically Significant Interactions with SUNLENCA Based on drug interaction studies conducted with SUNLENCA, no clinically significant drug interactions have been observed with:… (लेनाकैपाविर लेबल, दवाओं के इंटरैक्शन)

आप जो कुछ भी लेते हैं, उस सबके साथ रिस्पेरिडोन को जांचें। अपनी पूरी सूची जोड़ें; हर जोड़ी एक साथ जांची जाती है।

चेकर में खोलें

यह चिकित्सकीय सलाह नहीं है। गंभीरता लेबल के शब्दों को दर्शाती है, आपकी परिस्थितियों को नहीं। “गंभीर” चिह्न वाला संयोजन डॉक्टर की देखरेख में सामान्य बात हो सकता है, और “मामूली” चिह्न वाला संयोजन ऊंची खुराक पर मायने रख सकता है। फार्मासिस्ट से पूछें।